Raymond James Financial’s Sonnet BioTherapeutics SONN Stock Holding History

Raymond James Financial’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6	Closed	-$7	–	6509
2025 Q2	$7	Buy	+6	New	+$7	﹤0.01%	6948

Other funds holding SONN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's SONN Position: Q3 2025 in Review

Raymond James Financial sold out of Sonnet BioTherapeutics (SONN) in Q3 2025, closing a stake of 6 shares — an estimated $7 sold.

Raymond James Financial first reported a position in SONN in Q2 2025 and held it in 1 quarter. The position peaked at $7 in Q2 2025. 27 funds tracked by Wall St. Rank hold SONN as of Q3 2025.

Raymond James Financial reported no remaining Sonnet BioTherapeutics position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 6 Sonnet BioTherapeutics shares in Q3 2025, an estimated $7.
Raymond James Financial first reported a position in Sonnet BioTherapeutics in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Sonnet BioTherapeutics position peaked at $7 in Q2 2025.
27 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.